donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > MYGN Myriad Genetics > Detailed Quotes

MYGN Myriad Genetics

17.990
-0.450-2.44%
Trading Session 06/30 09:40 ET
High
19.074
Open
18.260
Turnover
84.97K
Low
17.720
Pre Close
18.440
Volume
4.66K
Market Cap
1.45B
P/E(TTM)
Loss
52wk High
36.955
Shares
80.34M
P/E(Static)
Loss
52wk Low
16.020
Float Cap
1.35B
Bid/Ask %
0.00%
Historical High
69.000
Shs Float
75.21M
Volume Ratio
0.32
Historical Low
1.438
Dividend TTM
--
Div Yield TTM
3700
P/B
1.52
Dividend LFY
--
Div Yield LFY
20566.98%
Turnover Ratio
0.01%
Amplitude
7.34%
Avg Price
18.223
Lot Size
1
Float Cap
1.35B
Bid/Ask %
0.00%
Historical High
69.000
Shs Float
75.21M
Volume Ratio
0.32
Historical Low
1.438
Dividend TTM
--
P/B
1.52
Dividend LFY
--
Turnover Ratio
0.01%
Amplitude
7.34%
Avg Price
18.223
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
CEO: Diaz, Paul J.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...